Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study
This article was originally published in The Pink Sheet Daily
Office of New Drugs Director John Jenkins reassured panel members of the agency’s ability to assess civil penalties or cite a drug for misbranding if sponsors fail to meet post-market study obligations.
You may also be interested in...
Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients
A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.